Mefloquine safety and tolerability in pregnancy: A systematic literature review

  • R. G
  • U. H
  • B. G
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Background: Control of malaria in pregnant women is still a major challenge as it constitutes an important cause of maternal and neonatal mortality. Mefloquine (MQ) has been used for malaria chemoprophylaxis in non-immune travellers for several decades and it constitutes a potential candidate for intermittent preventive treatment in pregnant women (IPTp). Methods. The safety of MQ, including its safety in pregnancy, is controversial and a continuing subject of debate. Published studies which evaluated the use of MQ for malaria prevention or treatment in pregnant women and which reported data on drug tolerability and/or pregnancy outcomes have been reviewed systematically. Results: Eighteen articles fitted the inclusion criteria, only one study was double-blind and placebo controlled. No differences were found in the risk of adverse pregnancy outcomes in women exposed to MQ compared to those exposed to other anti-malarials or to the general population. MQ combined with artesunate seems to be better tolerated than standard quinine therapy for treatment of non-severe falciparum malaria, but a MQ loading dose (10 mg/kg) is associated with more dizziness compared with placebo. When used for IPTp, MQ (15 mg/kg) may have more side effects than sulphadoxine- pyrimethamine. Conclusions: In the published literature there are no indications that MQ use during pregnancy carries an increased risk for the foetus. Ideally, the use of MQ to prevent malaria should be based on a risk-benefit analysis of adverse effects against the risk of acquiring the infection. For this purpose double-blinded randomized controlled trials in African pregnant women are much needed. © 2014 Gonzalez et al.; licensee BioMed Central Ltd.

Author-supplied keywords

  • *drug safety
  • *drug tolerability
  • *malaria falciparum/dt [Drug Therapy]
  • *malaria falciparum/pc [Prevention]
  • *mefloquine/ae [Adverse Drug Reaction]
  • *mefloquine/dt [Drug Therapy]
  • *pregnancy
  • adverse outcome
  • anorexia/si [Side Effect]
  • antimalarial agent
  • artesunate/dt [Drug Therapy]
  • article
  • congenital malformation
  • dizziness/si [Side Effect]
  • fetus risk
  • high risk pregnancy
  • human
  • malaria control
  • placebo
  • pregnancy outcome
  • pregnant woman
  • prophylaxis
  • pyrimethamine plus sulfadoxine/dt [Drug Therapy]
  • quinine/dt [Drug Therapy]
  • randomized controlled trial (topic)
  • risk benefit analysis
  • second trimester pregnancy
  • stillbirth
  • systematic review
  • third trimester pregnancy
  • tinnitus/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

There are no full text links


  • Gonzalez R.

  • Hellgren U.

  • Greenwood B.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free